Capsule-in-Capsule System for Controlled Cineole Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cineole-containing capsules for oral administration face challenges with optimal long-term stabilization, protection from oxidation, controlled release, and reduced side effects such as gastrointestinal issues, and do not always provide optimal dosing or taste masking.
Innovation Solution
A capsule-in-capsule system where 1,8-cineole is encapsulated within microcapsules using a miscible carrier like triglycerides, allowing for controlled release and improved stability, with an outer capsule shell resistant to gastric juice but soluble in the small intestine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cineole is administered systemically in conventional capsules, then it can be absorbed through the bloodstream and act in respiratory organs, but it causes gastrointestinal side effects such as gastric pressure, reflux, and nausea
Solution Approach 1:
The invention divides the single capsule into multiple microcapsules (inner capsules), each containing a portion of the cineole. This segmentation allows the total dose to be distributed across many small units, reducing the concentration of cineole in direct contact with the gastric mucosa while maintaining the total therapeutic dose, thereby reducing gastrointestinal side effects.
Solution Approach 2:
The invention uses a capsule-in-capsule system where multiple microcapsules (inner capsules) are nested within an outer capsule shell. The inner capsules contain the cineole dispersed in a carrier liquid, and the outer capsule provides gastric resistance. This nested structure protects the cineole from direct gastric contact while ensuring controlled release in the small intestine.
2Reliability
If cineole is administered in conventional capsules, then it provides expectorant and anti-inflammatory effects, but it does not provide optimal long-term stabilization and protection from oxidation
Solution Approach 1:
The nested capsule structure provides multiple protective barriers. The inner microcapsules protect the cineole from oxidation during storage, and the outer gastric-resistant capsule provides additional protection. This multi-layer protection system ensures long-term stabilization of the cineole composition while maintaining its therapeutic properties.
Solution Approach 2:
The carrier liquid used in the inner capsules creates an inert environment for the cineole, protecting it from oxidation during storage and transport. The encapsulation system isolates the cineole from atmospheric oxygen, maintaining its stability over long periods.
3Reliability
If cineole is administered in conventional capsules, then it can be delivered systemically, but it does not provide controlled release and requires multiple daily administrations
Solution Approach 1:
The capsule-in-capsule system enables controlled release by having the outer gastric-resistant capsule dissolve in the small intestine, followed by the gradual release of multiple inner microcapsules. This staged release mechanism extends the duration of action and allows for reduced dosing frequency while maintaining therapeutic effectiveness.
Solution Approach 2:
The outer capsule shell is designed to resist gastric juice and only dissolve in the small intestine, preliminarily protecting the cineole from premature release in the stomach. This preliminary action ensures that the cineole is released at the optimal location for absorption, extending its effective duration and reducing dosing frequency.
4Reliability
If cineole is administered in conventional capsules, then it provides therapeutic effects, but it does not provide optimal dosing precision or taste masking
Solution Approach 1:
By dividing the total cineole dose into multiple identical microcapsules, each containing a precise fraction of the total dose, the invention achieves better dosing precision. The uniform distribution of cineole across many small units allows for more accurate control of the amount released at each location in the small intestine.
Solution Approach 2:
The nested structure allows for precise encapsulation of the cineole in the inner capsules, with the outer capsule providing an additional layer of control. This multi-level encapsulation enables more precise dosing by controlling both the release location (via outer capsule dissolution) and the distribution pattern (via inner microcapsule dispersion).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This design enables controlled release of 1,8-cineole, enhances stability against oxidation, reduces gastrointestinal side effects, and allows for optimized dosing and taste masking, providing a more effective and tolerable treatment option with reduced daily dosing frequency.
Implementation Method 1
the inner capsules contain 1,8-cineole together with at least one physiologically acceptable carrier (excipient) which is miscible with 1,8-cineole and/or soluble therein
Implementation Method 2
enables controlled release of 1,8-cineole
Implementation Method 3
an outer capsule shell and a plurality of inner capsules located in the outer capsule... with an outer capsule shell
Implementation Method 4
soluble in the small intestine
Implementation Method 5
the inner capsules contain 1,8-cineole together with at least one physiologically acceptable carrier (excipient) which is miscible with 1,8-cineole and/or soluble therein
Implementation Method 6
the carrier being selected from the group of triglycerides
Data Source
AI summary
The invention relates to a cineole-containing dosage form for oral administration in capsule form, wherein the cineole-containing dosage form is designed as a capsule-in-capsule system, the capsule-in-capsule system comprising an outer capsule with an outer capsule shell and a plurality of inner capsules located within the outer capsule, wherein the inner capsules are completely surrounded by the capsule shell of the outer capsule and the inner capsules are designed as microcapsules, each containing the active ingredient 1,8-cineole. Furthermore, the present invention relates to the manufacture and use of this cineole-containing dosage form.